New subcutaneous formulation for vedolizumab monoclonal antibody, biotechnological drug with intestinal selectivity, already available in intravenous formulation for the treatment of adult patients with moderate to severe ulcerative colitis or active Crohn’s disease. There new method of administration in syringe or pre-filled pen, recently authorized by the Italian drug agency Aifa, represents “a turning point – Takeda announces – for all patients who were used to having to go to the hospital of reference for the infusion”, and who will now be able to “receive treatment directly at home or in a doctor’s office“, or also “self-administer the drug after adequate training by the reference specialist “.
Read Also
- Oppo may be contemplating to replace the Wifi by the Lifi Aug 17, 2020
- Amazon refund scam, the Codacons alarm: “Beware of false emails” Sep 20, 2021
- Sharp drop in soy prices: more than US $ 20 fell in Chicago Aug 30, 2021
- War in Ukraine: Winter has come to kyiv and the grain deal is picking up again Nov 17, 2022
- PlayStation Plus 12 months 50% off on PS Store, valid only for non-subscribers Aug 19, 2021
- Huawei would also organize a smartphone with a camera hidden under the screen Jun 3, 2020
- U.s. bank prohibits the application TikTok to its employees Jul 13, 2020